Boston Scientific cuts full-year organic growth outlook to 6.5%-8% and sets Q2 guidance at 5%-7% due to WATCHMAN, electrophysiology and urology weakness, as shares fall.
https://finviz.com/stock?t=BSX&p=d
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.